Literature DB >> 9568181

Correlation of immune cell activities and beta-endorphin release in breast carcinoma patients treated with galactose-specific lectin standardized mistletoe extract.

B M Heiny1, V Albrecht, J Beuth.   

Abstract

A prospectively randomized clinical study was performed with breast carcinoma patients to determine the correlation of defined parameters of the cellular immunity and beta-endorphin plasma levels after mistletoe lectin (ML-1) standardized therapy. The subcutaneous administration of optimal ML-1 dosages (0.5-1.0 ng ML-1/kg body weight; twice a week) induced an increased beta-endorphin plasma level, enhanced activity of peripheral blood natural killer (NK-)cells and T-lymphocytes (expression of CD-25/interleukin-2 receptors and HLA/DR-antigens). Statistical analysis of the data (Spearman correlation) revealed a significant correlation between NK- and T-cell activity and beta-endorphin plasma level. Thus, an obvious correlation between immune system and the neuroendocrine system may be anticipated which might gain therapeutical relevance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9568181

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

Review 1.  [Complementary and alternative medicine in urologic oncology].

Authors:  T Otto; J Suhr; H Rübben
Journal:  Urologe A       Date:  2003-11       Impact factor: 0.639

2.  Immunologic effector mechanisms of a standardized mistletoe extract on the function of human monocytes and lymphocytes in vitro, ex vivo, and in vivo.

Authors:  Lucie Heinzerling; Volker von Baehr; Christa Liebenthal; Rüdiger von Baehr; Hans-Dieter Volk
Journal:  J Clin Immunol       Date:  2006-05-17       Impact factor: 8.317

3.  Oncopharmacological Perspectives of a Plant Lectin (Viscum album Agglutinin-I): Overview of Recent Results from In vitro Experiments and In vivo Animal Models, and Their Possible Relevance for Clinical Applications.

Authors:  Tibor Hajtó; Katarina Hostanska; Timea Berki; László Pálinkás; Ferenc Boldizsár; Péter Németh
Journal:  Evid Based Complement Alternat Med       Date:  2005-01-28       Impact factor: 2.629

Review 4.  Preclinical and clinical effects of mistletoe against breast cancer.

Authors:  Mohsen Marvibaigi; Eko Supriyanto; Neda Amini; Fadzilah Adibah Abdul Majid; Saravana Kumar Jaganathan
Journal:  Biomed Res Int       Date:  2014-07-20       Impact factor: 3.411

Review 5.  Biological activity of mistletoe: in vitro and in vivo studies and mechanisms of action.

Authors:  Anna Szurpnicka; Anna Kowalczuk; Arkadiusz Szterk
Journal:  Arch Pharm Res       Date:  2020-07-03       Impact factor: 4.946

6.  Mistletoe lectin is not the only cytotoxic component in fermented preparations of Viscum album from white fir (Abies pectinata).

Authors:  Jenny Eggenschwiler; Leopold von Balthazar; Bianca Stritt; Doreen Pruntsch; Mac Ramos; Konrad Urech; Lukas Rist; A Paula Simões-Wüst; Angelika Viviani
Journal:  BMC Complement Altern Med       Date:  2007-05-10       Impact factor: 3.659

7.  Recombinant mistletoe lectin induces p53-independent apoptosis in tumour cells and cooperates with ionising radiation.

Authors:  K Hostanska; V Vuong; S Rocha; M S Soengas; C Glanzmann; R Saller; S Bodis; M Pruschy
Journal:  Br J Cancer       Date:  2003-06-02       Impact factor: 7.640

8.  European Mistletoe (Viscum album) Extract Is Cytotoxic to Canine High-Grade Astrocytoma Cells In Vitro and Has Additive Effects with Mebendazole.

Authors:  Anna Wright; Rie Watanabe; Jey W Koehler
Journal:  Vet Sci       Date:  2022-01-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.